Aug 2026· Antioxidants· Vol 15, pp. 979· 0 citations· 84 references
Medicine
TL;DR
This work establishes novel exploratory transcriptomic candidates for innovative consensus biomarkers and delineate cancer hallmark signatures specific to EC and CC, yielding novel diagnostic and prognostic insights into EAOC and supporting further study of subtype-associated expression programs.
Abstract
Background: Endometriosis-associated ovarian cancers (EAOCs), encompassing clear cell (CC) and endometrioid carcinomas (EC), constitute distinct biological entities yet lack robust biomarkers for precise classification, prognostication, and therapeutic decision-making in women. Therefore, we aimed to describe novel biomarkers. Methods: In this study, we conducted an integrated transcriptomic analysis, powered by machine learning, to discover novel consensus biomarkers and delineate cancer hallmark signatures specific to EC and CC. Drawing on gene expression profiles from EAOC specimens, we merged differential expression analysis with LASSO regression and Random Forest classification to generate a reliable biomarker panel that effectively distinguishes EC from CC. Kaplan–Meier survival analyses and mutation analyses have been performed for selected biomarker genes. Results: Novel biomarkers, among others, the genes RPS28, EPAS1, ALKBH2, and DCLRE1A, uncover extensive transcriptional alterations tied to hypoxia signaling, oxidative stress, DNA repair, and metabolic reprogramming. Gene Ontology and pathway enrichment analyses revealed synchronized upregulation of epithelial–mesenchymal transition, TNF-α/NF-κB signaling, oxidative stress, hypoxia, and KRAS signaling pathways. Conclusions: Our work establishes novel exploratory transcriptomic candidates for innovative consensus biomarkers, yielding novel diagnostic and prognostic insights into EAOC and supporting further study of subtype-associated expression programs. The current study was designed primarily as an integrative computational investigation aimed at identifying candidate genes and molecular pathways distinguishing CC from EC.
Findings indicate that NUSAP1 is a novel immunohistochemical marker with high specificity that can serve as an important complement to existing markers such as Cyclin D1 and BCOR, providing a new practical tool for the precise pathological diagnosis of HGESS.
Cheng Wang, Yuling Kou, Jing Zeng et al.· Archives of Pathology &...· 0 citations
In‑vitro experiments demonstrated that SLC12A8 modulates proliferation, invasion, and migration in both EM and EAOC cell lines, and support SLC12A8 as a candidate functional mediation and potential biomarker linked to EM‑EAOC pathological progression, thereby extending the mechanistic understanding of these disorders.
An overview of recent progress in multi-omics approaches is provided and significant miRNA-, lncRNA-, and exosome-related biomarkers associated with the initiation, progression, and therapeutic response of breast cancer are emphasized.
Kamyar Bagheri, Amirhossein Saberi, Maryam Zand et al.· Cancer Treatment and Researc...· 0 citations
Collectively, multi-modal plasma cfRNA profiling may enable non-invasive breast cancer detection and provide candidate markers for prognostic risk stratification and future precision oncology applications.
Jun Wang, Liu Yang, Kai Fang et al.· Genomics· 0 citations
ABSTRACT Epithelial ovarian cancer (EOC) is a heterogenous disease with frequent late-stage diagnosis and high mortality rates, for which no reliable screening tests exist. In recent years, epigenetic biomarkers in the form of DNA methylation in CpG-rich regions have gained increased attention in the scientific communi...
Hugo Swenson, Ella Ittner, Lucas Werner et al.· Epigenetics· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.